Inhibrx Biosciences, Inc.INBX

Inhibrx Biosciences (INBX) filed an 8-K on July 16 disclosing the departure of EVP and Chief Clinical Development Officer Josep Garcia, who joined in April 2023. This follows a Q1 2026 update showing the company burned $38 million in operating cash while recording just $1.3 million in annual revenue for 2025. Net loss attributable to shareholders widened to $-33.4 million in Q1 2026, with stockholders’ equity sinking to $-21 million.

The San Diego-based biotech pitches itself as a 'clinical-stage company anchored by protein-engineering expertise,' with two programs in clinical trials for cancer treatments. Its 'proprietary single-domain antibody platform' has attracted attention, but the financials tell a less polished story: R&D expenses consumed $25.2 million in Q1 alone, while cash reserves sat at $161.7 million-enough to fund roughly 4.2 quarters at current burn rates.

Despite touting 'differentiated mechanisms of action,' Inhibrx has yet to generate material product revenue. The company’s liability sheet ($205 million in liabilities vs. $184 million in assets) and consistent cash outflows suggest reliance on further capital raises, likely through share dilution. The recent executive departure adds uncertainty to its clinical trial timelines, which are critical for near-term catalysts.

Technical traders have no clear chart support here. The stock has no meaningful revenue stream, no buyback program to stabilize shares, and a liquidity profile that leans on periodic equity issuances. Without a near-term partnership or FDA breakthrough, the balance sheet remains the dominant force behind INBX’s trajectory.